Sai Life SciencesNSE:SAILIFE +1.35%18 ROE % is 16.79% as of Mar. 2026, which is 89% above its 10-year median of 8.89. GuruFocus rates NSE:SAILIFE with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Sai Life Sciences ranks better than 83.66% on this metric.
The historical rank and industry rank for Sai Life Sciences's ROE % or its related term are showing as below:
NSE:SAILIFE'
s ROE % Range Over the Past 10 Years
Min: 0.71 Med: 8.89 Max: 15.21
Current: 15.21
During the past 5 years, Sai Life Sciences's highest ROE % was 15.21%. The lowest was 0.71%. And the median was 8.89%.
NSE:SAILIFE's ROE % is ranked better than 83.66% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.31
vs NSE:SAILIFE: 15.21
Sai Life Sciences (NSE:SAILIFE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sai Life Sciences ROE % Related Terms
Sai Life Sciences ROE % Historical Data
* Premium members only.
The historical data trend for Sai Life Sciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Sai Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's ROE % distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Sai Life Sciences (NSE:SAILIFE) has a ROE % of 16.79% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sai Life Sciences and its competitors. This is 89% above median its historical median of 8.89. Over the past decade, Sai Life Sciences' ROE % has ranged from 0.71 to 15.21. According to the industry distribution chart, Sai Life Sciences ranks #33 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 16.3%.
Is Sai Life Sciences' ROE % too high?
Sai Life Sciences' current ROE % of 16.79% is 89% above median its 10-year median of 8.89. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 15.21. Based on the distribution chart, Sai Life Sciences ranks #33 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Life Sciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #33 out of 202 companies for ROE %. This places Sai Life Sciences in the top 16% of its industry — outperforming the majority of peers. Historically, Sai Life Sciences' own ROE % has ranged from 0.71 to 15.21 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current ROE % is 16.79%, which is 89% above median its own 10-year median of 8.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current ROE % of 16.79%. The current ROE % is 16.79%, which is 89% above median its 10-year median of 8.89. Sai Life Sciences' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current ROE % is 16.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
18GF Score
Get the complete analysis for NSE:SAILIFE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
